Overall, day two of ASCO GU emphasized that advances in therapy must go hand-in-hand with patient-centered research. These ...

Longitudinal PRO modeling, rather than time-to-worsening censoring, indicated maintained HRQOL and pain outcomes with ...

Cancers Symposium, and the updates were full of hope for people with advanced prostate cancer. CURE highlights two studies ...

Despite a trend toward more patient-centered research, quality-of-life end points remain substantially underreported in phase ...

Developing assertiveness is portrayed as a protective shift from people-pleasing and emotional suppression toward clearer ...

The bispecific ADC izalontamab brengitecan improved survival for patients with metastatic triple-negative breast cancer in a ...

The addition of Zytiga (abiraterone) to Truqap (capivasertib) significantly prolonged radiographic progression-free survival ...

Tibetan tingsha bells are used as a brief pre-event grounding intervention, leveraging sustained high-frequency resonance to ...

Kidney cancer is not exclusively a disease of older patients. For many young adults, the diagnosis comes as a shock, often appearing without warning in those who otherwise feel healthy.

Mehra added that research in head and neck cancer is entering an exciting phase, with growing interest in bispecific antibodies targeting EGFR. With newer dual-targeting agents, including Rybrevant, ...

Across the board, these experts emphasized that the 2026 ASCO GU Cancer Symposium will provide patients and clinicians with ...

At 7.3 years’ median follow-up, cabazitaxel failed to improve clinical PFS (62.8% vs 67.2%), metastasis-free survival, or overall survival versus androgen deprivation therapy plus radiotherapy.